← Leaderboards
Donald C Manning
Adynxx, Inc.
$2,858,544
Attributed
$5,717,088
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2019–20$5M$3.8M$2.5M$1.3M$0
'19
'20
Funding mix
By agency
NIH$5,717,088 · 1
By mechanism
UG3$5,717,088 · 1
Top collaborators
- Julien Mamet2 shared
Others in their field
Other Emerging Leaders on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$211,662,224
Research focus
BaseCaringClinically RelevantClinical Research SiteClinical TrialsDoseDouble-Blind MethodDrug CandidateEnrollmentFundingGrantHigh RiskHydrocodoneImplantImplantation ProcedureInstitutional Review BoardsKnee Replacement ArthroplastyMastectomyMeetingsNon-Opioid AnalgesicOperative Surgical ProceduresOpioidOpioid AnalgesicsAcute
Grant awards (2)
The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate$2,858,544
UG3 · FY2020 · DA
The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate$2,858,544
UG3 · FY2019 · DA